At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LSTA LISATA THERAPEUTICS INC
Closed Good Friday 04-17 16:00:00 EDT
2.26
+0.18
+8.44%
盘后2.26
+0.000.00%
17:40 EDT
| High2.26 | Low2.08 | Vol5.32K |
| Open2.24 | D1 Closing2.08 | Amplitude8.44% |
| Mkt Cap18.97M | Tradable Cap15.18M | Total Shares8.41M |
| T/O11.53K | T/O Rate0.08% | Tradable Shares6.73M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
BRIEF-Lisata Therapeutics- Will Evaluate Efficacy Of Certepetide
Reuters · 04-15
Lisata Therapeutics- Will Evaluate Efficacy of Certepetide, as Payload in Context of Catalent's Smartag ADC Dual-Payload Technology Platform
THOMSON REUTERS · 04-15
Lisata Therapeutics Announces Research License with Catalent
GlobeNewswire · 04-15
Press Release: Bladex and Scotiabank lead US$100 million loan for EGE Haina
Dow Jones · 03-13
Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ...
GuruFocus.com · 02-28
Lisata Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Reuters · 02-27
Lisata Therapeutics Inc: Cash Runway Extending Into Q2 of 2026 With No Debt
THOMSON REUTERS · 02-27
Lisata Therapeutics Inc expected to post a loss of 76 cents a share - Earnings Preview
Reuters · 02-25
BTN's Sustainable Finance Framework Receives Excellent Rating from Sustainable Fitch
Tempo · 02-23
BTN's Sustainable Finance Framework Receives Excellent Rating from Sustainable Fitch
Lisata Therapeutics and Warpnine Announce Encouraging Preliminary Results From the Phase 1B/2a Ilsta Trial Evaluating Certepetide in Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma
THOMSON REUTERS · 01-23
Lisata Therapeutics Shares Tumble After Pancreatic Cancer Treatment Results
Dow Jones · 01-22
US Stocks Higher; Netflix Profit Beats Estimates
Benzinga · 01-22
Lisata Therapeutics reports preliminary Cohort A data from Phase 2 ASCEND trial
TIPRANKS · 01-22
Lisata Therapeutics Inc - Data From Cohort B Expected in Coming Months
THOMSON REUTERS · 01-22
Lisata Therapeutics - Positive Trend in Overall Survival With 4 Complete Responses Related to Ongoing Phase 2 Ascend Trial
THOMSON REUTERS · 01-22
Lisata Therapeutics Reports Encouraging Preliminary Cohort A Data from the AGITG-led Phase 2 ASCEND Trial Evaluating Certepetide with Standard-of-Care Chemotherapy in Metastatic Pancreatic Ductal Adenocarcinoma
GlobeNewswire · 01-22
Beat the Market the Zacks Way: SoFi Technologies, Lisata Therapeutics, AutoZone in Focus
Zacks · 01-06
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial
Exec Edge · 2024-12-11
Lisata Therapeutics Completes Enrollment for Cancer Therapy Trial
Lisata Therapeutics Announces Completion of Enrollment in the Cendifox Trial
THOMSON REUTERS · 2024-12-10
Lisata Therapeutics Inc - Anticipate Reporting Results From Cendifox Trial in 2025
THOMSON REUTERS · 2024-12-10
Introduction
Company Name.
LISATA THERAPEUTICS INC
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App